Report Date: July 22, 2026 (before market open) | Fiscal Period: 2026Q2 | Current Price: ~$237 (down from a March 2026 all-time high of $329)
CME goes into this print in an unusual position: the underlying business just posted its best quarter ever, yet the stock has been one of the worst performers in financial services over the past four months. Shares are down roughly 28-30% from their March 2026 peak, and the sell-off has been driven almost entirely by structural/competitive and governance headlines rather than fundamentals — a dynamic that makes tomorrow's print (and, more importantly, management's commentary) unusually important for resetting the narrative.
Key context heading in: - Q1 2026 was a record quarter across the board: revenue of $1.9 billion (record), adjusted EPS of $3.36 (+20% y/y), and average daily volume (ADV) of 36.2 million contracts (+22% y/y), with records in all six asset classes simultaneously for the first time in company history. - Since then, the stock has round-tripped violently: from ~$285 at the Q1 print, up to ~$329 in mid-March, then down to a 52-week low near $220-$245 in June, before a partial recovery into the low-$240s ahead of tomorrow's report.
Consensus has drifted lower into the print: - The Zacks Consensus Estimate for CME's second-quarter revenues is pegged at $1.69 billion, indicating a 0.1% decrease from the year-ago reported figure, with earnings pegged at $2.93 per share, representing a slight year-over-year decline. - Other estimate services show similar figures — the consensus EPS estimate for the next earnings is $3.01 and the consensus revenue estimate is $1.74 billion — while Barchart/Nasdaq data points to EPS of $3.00 on a diluted basis, up 1.4% from $2.96 in the year-ago quarter. - Estimates have been trending down into the quarter: CME Group is expected to deliver a year-over-year increase in earnings on higher revenues... the consensus EPS estimate for the quarter has been revised 0.65% lower over the last 30 days... expected to post quarterly earnings of $2.98 per share. - Segment-level: the Zacks Consensus Estimate for clearing and transaction fees stands at $1.4 billion, a 1.7% decrease y/y; Agricultural ADV of 2.1 million contracts increased 6%; Equity Index ADV of 8.6 million contracts increased 13% y/y; and market data/information services revenue is pegged at $227 million, a 14.6% y/y increase. - Sentiment is lukewarm: CME's Zacks Rank sits at #4 (Sell) with a negative Earnings ESP, and last quarter the company posted $3.36 vs. $3.37 expected, a surprise of -0.30%, though it has beaten consensus EPS in three of the last four quarters.
The setup is a tough comp, not a demand problem. Q2 2025's ADV of 30.2 million contracts (already a record at the time) makes for a difficult year-over-year comparison against Q1 2026's blowout 36.2 million.
CME's monthly volume reports give a cleaner read than the headline y/y comparison: - April 2026: ADV reached 25.9 million contracts — a soft start. - May 2026: highest May ADV on record at 33.2 million contracts, up 15% year-over-year, with international ADV up 18% to 10.2 million contracts. - June 2026: ADV reached a new June record of 30.6 million contracts, up 19% year-over-year, and the company hit its second-highest Q2 volume ever, with 29.8 million contracts for the quarter overall.
In other words, volume reaccelerated sharply through the quarter (April weak, May/June record), even as the full-quarter average landed modestly below last year's Q2 due to the April lull. This is consistent with Keefe, Bruyette & Woods' view that the volume backdrop is improving heading into the second half.
This is the part of the story investors will be most focused on tomorrow.
On June 17, 2026, CME announced that Chairman & CEO Terry Duffy will transition to Executive Chairman on March 1, 2027, with President & CFO Lynne Fitzpatrick succeeding him as CEO. The company framed this as a long-planned, orderly succession — Duffy noted he has "never been more optimistic about its future potential" and that Fitzpatrick "is the right person at the right time" — but the market reacted negatively regardless. CME Group shares fell 4.90% on June 17, 2026, as investors digested the announcement that Chairman and CEO Terry Duffy will step down from the chief executive role in March 2027 and transition to Executive Chairman, with President and CFO Lynne Fitzpatrick, who has two decades at the company, taking over as CEO and joining the board.
The bigger overhang is regulatory: the CFTC issued an Order approving KalshiEX, LLC's listing of BTCPERP, a perpetual futures contract referencing the spot price of bitcoin, after determining it complies with the Commodity Exchange Act. This was a watershed moment because for the first time, a federal regulatory agency codified that perpetual futures belong in U.S. regulated markets, opening a new door after years of enormous volume flowing offshore. CME responded aggressively: CME sued the CFTC over approval of bitcoin perpetual futures for Kalshi and Coinbase, arguing they're swaps under Dodd-Frank, and CEO Terry Duffy has publicly argued "under the Dodd-Frank Act, it clearly defines what a swap is and what a future is, and when there's two parties exchanging payments to each other, that's deemed a swap." The CFTC has pushed back hard, with a spokesperson calling the suit "lawfare against the agency," saying "incumbents fear the future," and vowing to seek dismissal. This litigation is unresolved and represents a genuine tail risk to CME's crypto and (potentially) broader franchise if perpetuals expand into other asset classes — expect analyst questions on this topic tomorrow.
Separately, CME's push to launch 24/7 crude oil futures trading was halted when the CFTC exercised its authority to stay the self-certified contract pending a broader review of round-the-clock trading extensions — a reminder that CME's innovation agenda is currently running into regulatory friction on multiple fronts simultaneously.
Adding to the pressure, CME slid 5.7% as a new U.S. equity-index futures competitor went live in early June, reviving concerns about erosion of CME's dominant position in one of its most profitable product lines.
Collectively, the June selloff was driven by a confluence of factors including the announced CEO succession plan, regulatory approval of competing perpetual futures products, and a new equity-index futures competitor entering the market.
CME hasn't stood still. Recent announcements suggest an aggressive product pipeline designed to defend and extend its franchise heading into the print: - Equity index expansion: CME announced it would expand its benchmark suite of Equity Index futures with four new E-mini contracts — covering more than 90% of the entire U.S. investable market capitalization — starting June 29. - Single Stock Futures: CME will launch Single Stock futures across more than 50 top U.S. stocks on July 27, including 55 larger-sized and 22 Micro-sized contracts — a notable push into a product category historically dominated by other venues, timed just days after this earnings report. - New commodity products: CME is also launching 90% and 50% beef trim futures and options, filling a gap in risk-management tools between live cattle and processed beef products. - Cross-margining and capital efficiency: On the Q1 call, management highlighted that the FICC cross-margining program was expanding to end-user clients starting April 30, with COO Suzanne Sprague noting anticipated savings "upward of 80%" for the client book, building on a house program that had already delivered roughly $1.5 billion in peak daily savings. - Market data momentum: Q1 marked the 32nd consecutive quarter of year-over-year market data revenue growth, and analysts expect continued double-digit growth in Q2. - Prediction markets/FanDuel: As of the Q1 call, CME's event-contract/prediction-market volumes had surpassed 220 million contracts since the December 2025 launch, with markets-based (non-sports) contracts exceeding 30% of volume and over 150,000 new trading accounts opened — a long-term retail funnel management is counting on to feed the core futures franchise.
Sell-side reaction to the drawdown has been notably bifurcated: - Keefe, Bruyette & Woods upgraded CME Group's stock rating to Outperform from Market Perform, citing an attractive risk/reward opportunity following the decline, while Piper Sandler reiterated an Overweight rating with a $320 price target following the leadership change announcement. - KBW said the recent selloff creates an "extremely attractive" risk/reward, attributing the move to perceived perpetual futures risk that it views as overblown given CME's low retail exposure and index licenses in equities products, while also citing an improving volume backdrop into H2. - Rothschild & Co Redburn raised CME from "neutral" to "buy," boosting its price target from $316 to $323. - On the more cautious side, Erste Group Bank trimmed its FY2026 EPS estimate to $12.21 from $12.24 and maintains a "Hold" rating, and Zacks currently assigns CME a Rank #4 (Sell). - Average price targets remain well above the current quote — 21 analysts have an average price target of $313.58, implying upside of over 25% from current levels — underscoring how much the recent multiple compression reflects sentiment/narrative rather than a fundamental estimate reset.
CME enters this print with a business that continues to set volume records nearly every month, but a stock price that has been marked down for reasons that are largely about the future competitive/regulatory perimeter (perpetual futures, 24/7 trading, new equity-index entrants) and a leadership transition, rather than any deterioration in current demand. Q2 results themselves are likely to look "soft" only in relative terms — a slight y/y decline in revenue and EPS against a historically tough comp — while absolute profitability, margins, and capital efficiency metrics should remain near record levels. The more market-moving elements of tomorrow's release will likely be qualitative: how management frames the perpetual-futures competitive threat, the CFTC litigation, and the durability of its moat under incoming CEO Lynne Fitzpatrick — factors far more relevant to the stock's valuation multiple than this quarter's specific EPS beat or miss.